A fund created by the Bill & Melinda Gates Foundation to support private enterprise has awarded $5 million to Transimmune AG of Germany to enhance the potency of messenger RNA (mRNA) vaccines for the treatment of infectious diseases. Transimmune, which is a spin-out of Yale University in the US, will initially focus on a therapeutic vaccine for people living with HIV.
